newsfilter
← Interviews
Goldman Sachs9 min

The Surge in Global Biotech Innovation

Jerry Lee, Liz

Interview, Fireside Chat

In 2020, the biotech sector raised $55 billion in equity financing and pursued approximately $50 billion in M&A activity despite an initial pandemic pause, driven by supply-side advancements in genomic medicine and the urgent need for external innovation. Leading pharmaceutical giants like Pfizer, BioNTech, and Moderna deployed significant capital to develop vaccine candidates with high efficacy, while large-cap companies utilized substantial dry powder to acquire novel therapeutic technologies ahead of anticipated patent cliffs. Concurrently, cross-border collaboration shifted toward deep R&D partnerships between U.S., European, and Chinese entities, marking the emergence of Chinese biotechs as potential global competitors supported by government initiatives and a wave of returning scientific talent.